Skip to main content

Month: January 2025

Davis Commodities Limited and Kohai Jointly Engage in Strategic AI Investments

SINGAPORE, Jan. 21, 2025 (GLOBE NEWSWIRE) — Davis Commodities Limited (NASDAQ: DTCK), a global leader in commodities and logistics, and Kohai, an innovative gaming and eSports organization, today announced the signing of a Memorandum of Understanding (MOU) to jointly invest in Kinetic AI, a company that develops enterprise solutions using artificial intelligence (AI). Empowering Businesses with Innovative AI Solutions The global AI market is forecasted to surpass $1 trillion by 2030, showcasing the immense growth potential within the artificial intelligence sector. At the forefront of this transformative industry is Kinetic AI, a pioneering company specializing in crafting cutting-edge artificial intelligence solutions. Leveraging Tencent’s open-source AI language model and a range of advanced AI technologies, Kinetic AI...

Continue reading

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025. Halneuron® is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron® treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous...

Continue reading

Telos Corporation Achieves StateRAMP High Authorization

Cyber GRC solution Xacta is now included in the StateRAMP product list at the High impact level, reinforcing Telos’ commitment to cybersecurity for state and local government. ASHBURN, Va., Jan. 21, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced that it has successfully achieved State Risk and Authorization Management Program (StateRAMP) High authorization, signifying its commitment to robust cybersecurity practices and compliance with the StateRAMP security standards for state and local government agencies. The software-as-a-service (SaaS) version of Telos’ premiere cyber governance, risk and compliance (GRC) platform, Xacta®, has undergone a thorough evaluation and passed...

Continue reading

Global Mofy CEO Haogang Yang Awarded “Best CEO” at 9th Zhitong Finance Capital Market Annual Conference

BEIJING, Jan. 21, 2025 (GLOBE NEWSWIRE) — Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that the Company’s CEO, Haogang Yang, has been honored with the prestigious “Best CEO” award at the 9th Zhitong Finance Capital Market Annual Conference and Listed Company Awards Ceremony, held in Shenzhen, China, on December 11, 2024. The Zhitong Finance Capital Market Annual Conference, first launched in 2016, has evolved into a premier platform for recognizing outstanding performance among listed companies in the Hong Kong and US stock markets. Its influence and credibility have earned widespread acclaim from global investors,...

Continue reading

Coloplast A/S – Q1 2024/25 Earnings Release – Invitation to conference call on 4 February 2025 at 11.00am CET

Tuesday, 4 February 2025 at 10.00 – 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. Coloplast will be represented by: Kristian Villumsen – President & CEOAnders Lonning-Skovgaard – Executive Vice President, CFOAleksandra Dimovska – Vice President, Investor RelationsSimone Dyrby Helvind – Senior Manager, Investor Relations WebcastFor participants who do not wish to actively participate in the Q&A...

Continue reading

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin’s therapeutic window in soft-tissue sarcoma patients Combined mechanisms have the potential to enhance progression-free survival (PFS) in some of the largest cohorts of patients with soft-tissue sarcoma Topline safety data of the combination of SON-1010 with trabectedin is expected in H2 calendar year 2025 Sonnet management discusses what this expansion means in a Virtual Investor “What This Means” segment; Access here PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing...

Continue reading

OceanPal Inc. Announces the Sale of M/V Salt Lake City

ATHENS, Greece, Jan. 21, 2025 (GLOBE NEWSWIRE) — OceanPal Inc. (NASDAQ: OP) (the “Company”), a global shipping company specializing in the ownership of vessels, today announced that, through a separate wholly-owned subsidiary, it has signed a Memorandum of Agreement to sell to a third party, the 2005-built vessel “Salt Lake City”, with delivery to the buyer latest by February 20, 2025, for a sale price of US$16.1 million before commissions. Upon completion of the aforementioned sale, OceanPal Inc.’s fleet will consist of 3 Panamax dry bulk vessels and an MR2 tanker vessel. A table describing the current OceanPal Inc. fleet can be found on the Company’s website, www.oceanpal.com. Information contained on the Company’s website does not constitute a part of this press release. About the Company OceanPal Inc. is a global provider of...

Continue reading

Yerbae Expands Midwest Convenience Store Presence with Casey’s General Stores Authorization

SCOTTSDALE, Ariz., Jan. 21, 2025 (GLOBE NEWSWIRE) — Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, today announced a significant expansion of its retail footprint through a new partnership with Casey’s General Stores, one of the largest convenience store chains in the Midwest and Great Plains regions. This agreement will bring Yerbae’s refreshing and functional beverages to over 300 Casey’s locations, marking a key milestone in Yerbae’s growth strategy. Casey’s customers across multiple Midwestern states will now have access to Yerbae’s popular 12oz SKUs, including Mango Passionfruit, Black Cherry Pineapple, and Peachy Mimosa Twist. This partnership strategically positions Yerbaé to meet demand for healthier, plant-powered energy drinks within...

Continue reading

Yerbae Expands Midwest Convenience Store Presence with Casey’s General Stores Authorization

SCOTTSDALE, Ariz., Jan. 21, 2025 (GLOBE NEWSWIRE) — Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, today announced a significant expansion of its retail footprint through a new partnership with Casey’s General Stores, one of the largest convenience store chains in the Midwest and Great Plains regions. This agreement will bring Yerbae’s refreshing and functional beverages to over 300 Casey’s locations, marking a key milestone in Yerbae’s growth strategy. Casey’s customers across multiple Midwestern states will now have access to Yerbae’s popular 12oz SKUs, including Mango Passionfruit, Black Cherry Pineapple, and Peachy Mimosa Twist. This partnership strategically positions Yerbaé to meet demand for healthier, plant-powered energy drinks within...

Continue reading

Ensurge Micropower ASA – Notice of Extraordinary General Meeting 11 February 2025

An Extraordinary General Meeting in Ensurge Micropower ASA (the “Company”) will be held on 11 February 2025 at 09:00 (CET) as an electronic meeting. Please find enclosed the notice including attendance forms and online guides (in English and in Norwegian). The Extraordinary General Meeting will have the following agenda:  1 Registration of participating shareholders; election of a person to chair the meeting and a person to co-sign the minutes  2 Approval of the notice and agenda  3 Issue of Warrants  4.1 Board authorization to issue shares in private placements  4.2 Board authorization to issue shares in rights issues  About Ensurge Micropower  Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.